Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 9/20 | 0.54 |
| ▸ | RHEB | Q15382 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651824 | 0.96 | PRSS12 (0.54) | PRSS12RHEBHDAC6KDRHDAC4 | |
| SCHEMBL5649071 | 0.92 | PRSS12 (0.62) | PRSS12RHEBHDAC6HDAC4HDAC2 | |
| SCHEMBL5649502 | 0.90 | PRSS12 (0.55) | PRSS12RHEBHDAC6HDAC4HDAC2 | |
| SCHEMBL5652123 | 0.89 | TP53 (0.46) | PRSS12HDAC6KDRHTTTSHR | |
| SCHEMBL5649514 | 0.88 | PRSS12 (0.55) | PRSS12RHEBHDAC6HDAC4HDAC2 | |
| SCHEMBL5648685 | 0.88 | TP53 (0.47) | PRSS12HDAC6HTTTP53SMN1; SMN2 | |
| SCHEMBL5653446 | 0.87 | TP53 (0.44) | PRSS12HDAC6HTTTSHRMAPK1 | |
| SCHEMBL5652788 | 0.86 | PRSS12 (0.54) | PRSS12RHEBKDR | |
| SCHEMBL5649315 | 0.85 | HDAC6 (0.54) | PRSS12HDAC6HDAC4HDAC2HDAC8 | |
| SCHEMBL5652128 | 0.85 | TP53 (0.46) | PRSS12HDAC6KDRHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | PRSS12 979/4885RHEB 946/4885HDAC6 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.